Common Hawthorn for Health & Longevity - Quick Reference Sheet

Common Hawthorn for Health & Longevity

Created on 07/07/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Common Hawthorn is a gentle, well-tolerated heart botanical, used as a standardized leaf-and-flower extract. Its strongest evidence supports easing symptoms and improving exercise ability in mild, early heart weakness. Effects on blood pressure, cholesterol, lifespan, and major heart events remain weak or unproven. The main caution is overlap with heart and blood-pressure medicines. (Full Review)

Protocol

Standard Dose
160–900 mg/day
Standardized to ~18.75% oligomeric procyanidins or ~2.25% flavonoids
Form
Standardized extract
Leaf-with-flower dry extract (e.g., WS 1442, LI 132)
Frequency
2–3 divided doses
Taken with food to reduce stomach upset
Time to effect
Symptom Relief
Several weeks
Breathlessness and fatigue ease gradually
Judge Response
6–8 weeks
Realistic point before assessing exercise-capacity benefit
Trial Window
4–24 weeks
Range at which trials measured outcomes

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Severe or decompensated heart failure (NYHA class IV)
  • Symptomatic low blood pressure
  • Children
Key Interactions
  • Cardiac glycosides (digoxin, digitoxin)
  • Antihypertensive drugs (ACE inhibitors, ARBs, calcium channel blockers, diuretics)
  • Nitrates and PDE5 inhibitors (nitroglycerin, sildenafil)
  • Beta-blockers (metoprolol, carvedilol) and antiarrhythmics (amiodarone)
  • Over-the-counter decongestants and camphor-containing products
  • Supplements with additive blood-pressure or blood-flow effects (garlic, hibiscus, magnesium, CoQ10, L-arginine)
  • Anticoagulant/antiplatelet agents (warfarin, aspirin)

Risk & Side Effects

  • High: Mild digestive upset and dizziness
  • Medium: Interactions with cardiovascular drugs
  • Low: Palpitations, headache, and fatigue; blood-pressure increase from camphor-hawthorn combinations
  • Speculative: Uterine stimulation in pregnancy; additive sedation and hypotension in combination products

Monitoring

Marker Target Why
Blood pressure ~110–125 / 70–80 mmHg Detects additive hypotension and tracks any vascular benefit
Resting heart rate 55–70 bpm Screens for additive effects on rate/rhythm
Exercise tolerance (functional capacity) Improvement over baseline Primary success marker in mild heart failure
NT-proBNP Trending down or stable, ideally <125 pg/mL Reflects cardiac wall stress in heart failure
Left ventricular ejection fraction ≥55% (or stable/improved) Tracks pumping efficiency if heart failure is present
Lipid panel TC <200; HDL >50; TG <100 mg/dL Assesses any modest lipid effect
Digoxin level (if co-administered) 0.5–0.9 ng/mL Guards against additive glycoside effect
eGFR (kidney function) >60 mL/min/1.73m² Contextualizes cardiac markers and drug clearance

Cadence: Baseline check, reassess at 6–12 weeks to judge response and tolerability, then every 6–12 months; more frequent blood-pressure checks in the first weeks if combined with antihypertensives.

Qualitative Assessment

  • Reduced breathlessness and fatigue during everyday exertion
  • Improved exercise tolerance and sense of stamina
  • Overall subjective well-being and energy
  • Absence of dizziness, palpitations, or lightheadedness suggesting excessive additive effects